microRNA-144 functions as a diagnostic and prognostic marker for retinoblastoma

Qian Zheng, Qin Zhu, Cuiping Li, Shuang Hao, Jianguo Li, Xin Yu, Dengmei Qi, Yu Pan*

Department of Ophthalmology, Zibo Maternal and Child Health Hospital, Zibo 255029, China.

Zheng Q, Zhu Q, Li C, Hao S, Li J, Yu X, et al. microRNA-144 functions as a diagnostic and prognostic marker for retinoblastoma. Clinics. 2020;75:e1804

*Corresponding author. E-mail: dr_qianzheng@outlook.com

OBJECTIVES: Retinoblastoma (RB) is a highly malignant eye tumor with a low survival rate and a high metastatic rate. The current work was designed to investigate the potential roles of microRNA-144 (miR-144) in the diagnosis and prognosis of RB.

METHODS: miR-144 expression levels in RB tissues and adjacent normal tissues, as well as serum samples from RB patients and healthy controls were measured. The association between miR-144 expression levels and clinical features were analyzed. Moreover, diagnostic and prognostic values of miR-144 in RB were verified by receiver operating characteristic analysis and Kaplan-Meier survival assays.

RESULTS: The expression level of miR-144 was markedly decreased in tumor tissues of RB patients, and the expression level of miR-144 was positively associated with tumor size and metastasis in RB patients. Moreover, miR-144 can distinguish tumor tissues from normal tissues with high specificity and sensitivity, and RB patients with lower miR-144 expression have shorter overall and disease-free survival rates than those with higher miR-144 expression. Alternatively, miR-144 also decreased in the serum of RB patients in comparison with healthy subjects, and miR-144 expression levels in the tissue samples and serum were positively correlated. Furthermore, miR-144 levels in the serum of RB patients sensitively distinguished RB patients from healthy controls.

CONCLUSIONS: miR-144 expression was downregulated in serum and tissue samples of RB patients and may function as a diagnostic and prognostic marker for RB.

KEYWORDS: Retinoblastoma; miR-144; Diagnosis; Prognosis.

INTRODUCTION

Retinoblastoma (RB) is a common eye malignant tumor and the most common type of tumor in children. According to previous studies, RB shows rapid growth, a high metastatic rate, and poor prognosis (1-3). With the development of modern technology, the survival rate of RB has increased to over 50% (4,5). However, long-term prognosis of RB patients is still unfavorable, and among children who survive, some lose their vision (1). Therefore, it is important to explore the underlying mechanisms involved in RB tumorigenesis, development, and prognosis.

MicroRNAs represent a class of short non-coding RNAs with a length of approximately 20 nucleotides. MicroRNAs (miRNAs) are able to bind to the 3’ UTR of their target genes and inhibit the expression of the target genes at the post-transcriptional level (6,7). Accumulating evidence has reported that miRNAs regulate different cellular behaviors, e.g., cell growth, apoptosis, migration, invasion, and differentiation (7-9). According to various studies, several miRNAs (miR-936, miR-23-5p, miR-140-5p) were dysregulated in RB patients, thereby mediating the development and metastasis of RB (10-14).

MicroRNA-144 (miR-144) is a member of the miRNA family. Dysregulation of miR-144 was verified in various tumors; miRNAs function either as tumor suppressors or onco-miRNAs (15-19). However, the role of miR-144 with regard to the diagnostic and prognostic values of RB has not yet been elucidated. Hence, the aim of this study was to explore the potential clinical value of miR-144 for the diagnosis and treatment of RB.

MATERIALS AND METHODS

Samples

A total of 50 RB tumor tissues and paired adjacent tissues were used in this study. Samples were obtained from children hospitalized at Zibo Maternal and Child Health Hospital who underwent enucleation surgery between July 2011 and May 2014. In addition, serum samples of these patients and 50 healthy controls were also collected. Written informed consent was provided by all study participants. This study was approved by the Ethics Committee of Zibo Maternal and Child Health Hospital. All RB patients were confirmed based on clinical manifestations and imaging results without receiving any adjuvant therapy prior to...
surgery. Samples were collected from all participants and frozen at -80°C for subsequent examination.

Clinical information of patients was collected and is shown in Table 1. The 5-year follow-up analysis was updated telephonically every 5 months.

Real-time PCR
To examine the expression level of miR-144, real-time PCR was performed. Briefly, total RNA was isolated from tissue and blood samples using the TRIzol reagent (Invitrogen, Carlsbad, USA). Concentrations of RNA samples were evaluated based on their absorbance ratio at 260 nm/280 nm, according to the manufacturer's instructions (ThermoScientific NanoDrop Technologies, Wilmington, DE, USA). Thereafter, cDNA was reverse-transcribed using the commercially available Reverse Transcription Kit (Invitrogen). The PCR was conducted using the ABI 7500 system (Applied Biosystems, Inc., USA) with the SYBR Green kit (Invitrogen) according to the manufacturer’s instructions. miR-144 expression in each sample was normalized to that of U6. The primer sequences used were: miR-144 forward, 5'-TGCGGTACAGTATAGATGAT-3' and reverse, 5'-CCAGTGCAGGGTCCGAGGT-3'; U6 forward, 5'-TGCGGGTGCTCGCTTCGGCAGC-3, and reverse 5'-CCAGTGCAGGGTCCGAGGT-3'.

Statistical analysis
SPSS 22.0 and GraphPad statistical software were used for data analysis. All experimental data were expressed as the means ± standard deviations. The differences between two groups were compared using the Student's t-test. The diagnostic value of miR-144 was evaluated by receiver operating characteristic (ROC) curve analysis. The Kaplan-Meier was used to determine the overall survival (OS) and disease-free survival (DFS) of patients. The clinical information in Table 1 was analyzed by the chi-square test. p-values less than 0.05 were considered statistically significant.

RESULTS
Downregulation of miR-144 expression in RB tumor tissues compared with non-tumor tissues
miR-144 levels in the tumor samples of 50 RB patients and 50 matched non-tumor adjacent tissue samples were compared by RT-qPCR assays. As shown in Figure 1, the miR-144 level markedly decreased in RB tumors in comparison with non-tumor tissue (p<0.001). Moreover, RB patients have been divided into the miR-144-high group (n=23, delta ct of miR-144<median value 9.6) and miR-144-low group (n=27, delta ct of miR-144>median value 9.6) based on miR-144 levels. As seen in Table 1, we found that decreased miR-144 levels may indicate increased tumor size (p<0.05), advanced clinical stage (p<0.01), and an increased chance of metastasis (p<0.01).

MiR-144 expression in RB tumor tissues may serve as a diagnostic and prognostic marker for RB
ROC analysis was performed to analyze the potential diagnostic value of miR-144 for RB. As shown in Figure 2A, the area under the curve (AUC) of miR-144 was 0.9312 (95% confidence interval 0.8765 to 0.9859; cut-off value, 8.634; sensitivity, 98%; specificity, 82%), suggesting that the miR-144 level is a sensitive biomarker for the diagnosis of RB; moreover, the prognostic value of miR-144 was also analyzed...
by the Kaplan-Meier method. We found that during the 5-year follow-up period, the miR-144 low group decreased the OS (Figure 2B, \(p=0.0065\)) and DFS, when compared with the miR-144-high group (Figure 2C, \(p=0.0331\)).

Decreased miR-144 expression in the serum of RB patients

miR-144 levels in serum samples of 50 patients and healthy controls were also compared. It was observed that miR-144 levels decreased markedly in serum samples of RB patients in comparison with the healthy controls (Figure 3A, \(p<0.01\)). Moreover, correlation analysis demonstrated that miR-144 levels in tissue and serum samples of RB patients were positively correlated (Figure 3B, \(r=0.2848, p=0.0459\)).

Circulating miR-144 levels may serve as a potential diagnostic marker for RB

Finally, we performed ROC analysis to determine the potential diagnostic value of circulating miR-144 levels in distinguishing RB patients from healthy controls. As shown in Figure 3C, the AUC of circulating miR-144 was 0.8860 (95% confidence interval, 0.8232 to 0.9488; cut-off value, 8.499; sensitivity, 80%; specificity, 80%), suggesting that circulating miR-144 is a sensitive biomarker for the diagnosis of RB.

DISCUSSION

The current work focused on the roles of miR-144 in the pathogenesis of RB. We observed that miR-144 expression was markedly decreased in tumor tissues and serum samples of RB patients, and that miR-144 may function as a potential diagnostic and prognostic biomarker.

Numerous studies have suggested that dysregulation of miR-144 may contribute to the development of different types of cancers. For instance, it has been reported that miR-144 could inhibit growth and metastasis of breast cancer cells by targeting CEP55 (15). Moreover, miRNA-144 has been reported to regulate the carcinogenic behavior of gastric cancer cells (19) and alleviate the cisplatin resistance of cervical cancer cells (20). However, whether miR-144 is involved in the pathogenesis of RB remains unclear. In the present study, we found that miR-144 expression was markedly decreased in RB tumor tissues. This decreased level of miR-144 was associated with increased tumor size, advanced clinical stage, as well as increased metastasis. Overall, our data suggested that miR-144 expression was downregulated in RB and that it may function as a tumor suppressor.

Increasing evidence has proposed the potential use of miRNAs as diagnostic and prognostic biomarkers for cancers. The potential diagnostic and prognostic value of miRNAs, and the roles of miRNAs in RB as biomarkers have been discussed previously (21). Alternatively, the roles of miR-144 as potential biomarkers in other cancers have also been discussed. In the present study, we found that the AUC of miR-144 was 0.9312 suggesting that miR-144 is a sensitive biomarker for distinguishing RB tumor tissues from adjacent normal tissues. Moreover, results of the survival analysis indicated that decreased miR-144 expression may indicate poor prognosis. Therefore, the results of the current study suggested that miR-144 may function as a potential diagnostic and prognostic biomarker for the diagnosis and treatment of RB.

The above data has indicated the diagnostic value of miR-144 levels in RB tumors; however, in clinical situations, it is inconvenient to obtain tissue samples for diagnostic purposes. A few recent studies have suggested that miRNAs can be released by tumor tissue and that their levels can be stably maintained in the blood. Therefore, to detect miRNA expression in blood samples (so-called circulating miRNAs) may be a cheap and easy method for the early diagnosis of different diseases (22-24). Studies on circulating miRNAs with regard to RB are limited. Zhou et al. suggested that miR-338-5p levels in the serum of RB patients may function as
potential biomarkers (21). Notably, we found that circulating miR-144 levels were also downregulated in RB patients, and that the expression of miR-144 in RB tumor tissues and that in serum samples were negatively correlated. These results suggested that the aberrant decrease in miR-144 expression in the serum of RB patients was primarily due to the formation of tumor tissues. Moreover, the results of ROC analysis confirmed the diagnostic value of circulating miR-144 levels for RB, which was consistent with levels of tissue-expressed miR-144.

In summary, the present work revealed that decreased miR-144 expression may serve as a potential diagnostic and prognostic biomarker for RB. However, these results require confirmation using a larger sample size in future investigations.

**AUTHOR CONTRIBUTIONS**

Zheng Q was responsible for the data curation, investigation, methodology, and writing manuscript original draft. Zhu Q was responsible for the formal analysis, investigation, methodology, and validation. Li C was responsible for the formal analysis, methodology, and software resources. Hao S was responsible for the data curation and software resources. Li J was responsible for the investigation, methodology, and validation. Yu X was responsible for the data curation, methodology, and software resources. Qi D was responsible for the formal analysis, and investigation. Pan Y was responsible for the conceptualization, manuscript original draft, editing and review.

**REFERENCES**

1. Jiménez I, Laé M, Tanguy ML, Savignoni A, Gauthier-Villars M, Desjar-
dins L, et al. Craniofacial second primary tumors in patients with germ-
line retinoblastoma previously treated with external beam radiotherapy:
A retrospective institutional analysis. Pediatr Blood Cancer. 2020;67(4):
2185. https://doi.org/10.1002/pbc.28138
2. Qureshi S, Francis JH, Haque SS, Dunkel IJ, Souweidane MM, Friedman
DN, et al. Magnetic Resonance Imaging Screening for Trilateral Retino-
blastoma: The Memorial Sloan Kettering Cancer Center Experience 2006-
2016. Ophthalmo Retina. 2020;4(3):327-35. https://doi.org/10.1016/j.
oret.2019.10.010
3. Chen HM, Ong SJ, Chao AN, Liu KL, Jung SM, Kao IY. Histopathologic
findings after selective ophthalmic arterial injection of melphanal for
retinoblastoma. Taiwan J Ophthalmol. 2019;9(4):262-6. https://doi.org/
10.4103/to.tj.2019.14_19
4. Zia N, Hamid A, Ikikhar S, Qadri MH, Jangda A, Khan MR. Retinob-
blastoma Presentation and Survival: A four-year analysis from a tertiary
care hospital. Pak J Med Sci. 2020;36(1):561-566. https://doi.org/
10.12669/pjms.36.ICON-Suppl.1720
5. Yang S, Liu T, Cheng H, Wang Z, Feng Y, Yan J, et al. Decreased Expression
of Retinoblastoma Protein-Interacting Zinc-Finger Gene 1 Is Correlated
With Poor Survival and Aggressiveness of Cervical Cancer Patients. Front
Oncol. 2019;9:1396. https://doi.org/10.3389/fonc.2019.01396
6. Yang C, Jia R, Zuo Q, Zheng Y, Wu Q, Luo B, et al. microRNA-143-3p
odontogenic differentiation of human dental pulp stem cells through
regulation of the osteoprotegerin-RANK ligand pathway by targeting
RANK. Exp Physiol. 2020;105(5):876-85. https://doi.org/10.1113/EP0
87992
7. Wang Y, Shi S, Zhang Q, Dong H, Zhang J. MicroRNA-206 upregulation
relieves circTCF25-induced osteosarcoma cell proliferation and migration.
J Cell Physiol. 2020;2020:10.1002/jcp.29570
8. Tian P, Tao L, Wang Y, Han X. MicroRNA-127 Inhibits the Progression
of Melanoma by Downregulating Delta-Like Homologue 1. Biomed Res Int.
2020;2020:8523465. https://doi.org/10.1155/2020/8523465
9. Li Y, Liu J. MicroRNA-206 predicts raised fetal growth retardation risk through the interaction with vascular endothelial growth factor in
pregnancies. Medicine (Baltimore). 2020;99(7):e18897. https://doi.org/
10.1097/MD.0000000000018892
10. Xu L, Li W, Shi Q, Wang M, Li H, Yang X, et al. MicroRNA936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and
deviating the PI3K/Akt pathway. Oncol Rep. 2020;43(2):635-45. https://doi.org/10.3892/or.2020.75356
11. Wan W, Wan W, Long Y, Li Q, Jin X, Wan G, et al. MiR-25-3p promotes
malignant phenotypes of retinoblastoma by regulating PTEN/Akt path-
way. Biomed Pharmacother. 2019;118:109111. https://doi.org/10.1016/
ji.biopha.2019.10.9111
12. Liu Y, Yin X, Deng Y, Peng X. MiR-140-3p suppresses retinoblastoma cell
growth via inhibiting c-Met/AKT/mTOR pathway. Biosci Rep. 2018;
38(6):BSR20180776. https://doi.org/10.1042/BSR20180776

Figure 3 - Decreased miR-144 expression in the serum of retinoblastoma (RB) patients. A. Comparison of miR-144 levels in serum of RB patients and healthy controls. B. Correlation between miR-144 levels in RB tumor and serum samples of RB patients. C. Results of receiver operating characteristic (ROC) analysis for circulating RB. **p<0.01.
13. Chen Z, Yang H, Nie Y, Xing Y. miR-145 regulates the proliferation and apoptosis of Y79 human retinoblastoma cells by targeting IGF-1R. Int J Clin Exp Pathol. 2018;11(9):4331-8.

14. Wu L, Chen Z, Xing Y. MiR-506-3p inhibits cell proliferation, induces cell cycle arrest and apoptosis in retinoblastoma by directly targeting NEK6. Cell Biol Int. 2018. https://doi.org/10.1002/cbin.11041

15. Yin Y, Cai J, Meng F, Sui C, Jiang Y. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55. Cancer Biol Ther. 2018;19(4):306-15. https://doi.org/10.1080/15384047.2017.1416934

16. Han S, Zhu J, Zhang Y. miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1. Med Sci Monit Basic Res. 2018;24:40-6. https://doi.org/10.12659/MSMBR.907333

17. Tao P, Wen H, Yang B, Zhang A, Wu X, Li Q. miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC. Exp Ther Med. 2018;15(1):562-8. https://doi.org/10.3892/etm.2017.5392

18. Liu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018; 26(5):683-90. https://doi.org/10.3727/096504017X14982565511252

19. Ren K, Liu QQ, An ZF, Zhang DP, Chen XH. MiR-144 functions as tumor suppressor by targeting PIM1 in gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21(13):3028-37.

20. Shi F, Su J, Liu Z, Wang J, Wang T. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2. J Cell Biochem. 2019;120(9):15018-26. https://doi.org/10.1002/jcb.28763

21. Zhou P, Li X. Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. Oncol Lett. 2019;18(1):307-13. https://doi.org/10.3892/ol.2019.10331

22. Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. Mol Aspects Med. 2020;72:100825. https://doi.org/10.1016/j.mam.2019.10.002

23. Su T, Shao X, Zhang X, Yang C, Shao X. Value of circulating miRNA-1 detected within 3h after the onset of acute chest pain in the diagnosis and prognosis of acute myocardial infarction. Int J Cardiol. 2020;307:146-51. https://doi.org/10.1016/j.ijcard.2019.09.050

24. Penyige A, Márton É, Soltész B, Szilágyi-Bónizs M, Póka R, Lukács J, et al. Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients. Int J Mol Sci. 2019;20(18):4533. https://doi.org/10.3390/ijms.20184533